Rossari Biotech's Q1 FY 2026-27 Quarterly Results
- 19 Jul 2026
Result Summary
- Rossari Biotech Ltd reported a 0.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 28.5%.
- Its expenses for the quarter were up by 2.0% QoQ and 30.8% YoY.
- The net profit decreased 23.6% QoQ and increased 4.5% YoY.
- The earnings per share (EPS) of Rossari Biotech Ltd stood at 6.33 during Q1 FY 2026-27.
Financial Statments for Q1 FY 2026-27
(₹ crores) | Q1FY27 | Q4FY26 | Q1FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 700.39 | 703.93 | 544.92 | -0.5% | 28.5% |
Total Expenses | 653.18 | 640.20 | 499.34 | 2.0% | 30.8% |
Profit Before Tax | 47.22 | 63.73 | 45.58 | -25.9% | 3.6% |
Tax | 12.58 | 18.28 | 12.50 | -31.2% | 0.6% |
Profit After Tax | 35.10 | 45.97 | 33.60 | -23.6% | 4.5% |
Earnings Per Share | 6.33 | 8.29 | 6.06 | -23.6% | 4.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Rossari Biotech Ltd is a prominent player in the chemical manufacturing industry with a focus on producing specialty chemicals. The company primarily engages in the production of home, personal care, and performance chemicals. It also has a significant presence in the textile specialty chemicals segment. Rossari Biotech has been known for its innovative solutions and sustainability-driven approach, catering to a diverse range of industrial applications. Recent developments in the company include strategic expansions and partnerships to enhance its product portfolio and market reach. However, specific recent major developments were not available in the provided data.
Revenue
In the first quarter of the fiscal year 2027 (Q1FY27), Rossari Biotech Ltd reported a total income of ₹700.39 crores. This represents a slight decrease of 0.5% compared to the previous quarter (Q4FY26), where total income was ₹703.93 crores. On a year-over-year basis, total income increased significantly by 28.5% from ₹544.92 crores in Q1FY26. This growth in revenue reflects the company's expansion efforts and possibly increased demand for its products within the market.
Profitability
Rossari Biotech's profitability metrics for Q1FY27 indicate a profit before tax of ₹47.22 crores. This marks a decline of 25.9% from the previous quarter's profit before tax of ₹63.73 crores. Compared to the same quarter in the previous year (Q1FY26), however, there is a modest increase of 3.6% from ₹45.58 crores. The profit after tax for Q1FY27 stands at ₹35.10 crores, showing a decrease of 23.6% from the previous quarter's ₹45.97 crores, but a growth of 4.5% year-over-year from ₹33.60 crores. Earnings per share followed a similar trend, decreasing to ₹6.33 in Q1FY27 from ₹8.29 in the previous quarter, yet showing an increase from ₹6.06 in Q1FY26.
Operating Metrics
During Q1FY27, Rossari Biotech Ltd's total expenses amounted to ₹653.18 crores, reflecting a growth of 2.0% from Q4FY26, where expenses were ₹640.20 crores. Year-over-year, total expenses increased by 30.8% from ₹499.34 crores in Q1FY26. The tax expense for the quarter was ₹12.58 crores, which decreased by 31.2% from the previous quarter's ₹18.28 crores, and showed a slight increase of 0.6% compared to ₹12.50 crores in the same quarter of the previous year. These metrics indicate the company's ongoing operational costs and tax implications during the quarter.
FAQs
Rossari Biotech Ltd announced its Q1 FY 2026-27 results on 19 July, 2026.
Rossari Biotech Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Rossari Biotech Ltd Q1 FY 2026-27 results include:
- Revenue: ₹700.39 crore
- Net Profit: ₹35.10 crore
- EBITDA: ₹83.81 crore
- Year-over-Year Growth: 28.5%
- Quarter-over-Quarter Growth: -0.5%
Rossari Biotech Ltd reported a net loss of ₹35.10 crore in Q1 FY 2026-27, reflecting a 4.5% year-over-year growth.
Rossari Biotech Ltd posted a revenue of ₹700.39 crore in Q1 FY 2026-27.